Download MendeleyDiscovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer.
Eno, M.S., Brubaker, J.D., Campbell, J.E., De Savi, C., Guzi, T.J., Williams, B.D., Wilson, D., Wilson, K., Brooijmans, N., Kim, J., Ozen, A., Perola, E., Hsieh, J., Brown, V., Fetalvero, K., Garner, A., Zhang, Z., Stevison, F., Woessner, R., Singh, J., Timsit, Y., Kinkema, C., Medendorp, C., Lee, C., Albayya, F., Zalutskaya, A., Schalm, S., Dineen, T.A.(2022) J Med Chem 65: 9662-9677
- PubMed: 35838760
- DOI: https://doi.org/10.1021/acs.jmedchem.2c00704
- Primary Citation of Related Structures:
8D73, 8D76 - PubMed Abstract:
While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the treatment landscape for EGFR mutant (L858R and ex19del)-driven non-small-cell lung cancer (NSCLC), most patients will eventually develop resistance to TKIs. In the case of first- and second-generation TKIs, up to 60% of patients will develop an EGFR T790M mutation, while third-generation irreversible TKIs, like osimertinib, lead to C797S as the primary on-target resistance mutation. The development of reversible inhibitors of these resistance mutants is often hampered by poor selectivity against wild-type EGFR, resulting in potentially dose-limiting toxicities and a sub-optimal profile for use in combinations. BLU-945 (compound 30 ) is a potent, reversible, wild-type-sparing inhibitor of EGFR+/T790M and EGFR+/T790M/C797S resistance mutants that maintains activity against the sensitizing mutations, especially L858R. Pre-clinical efficacy and safety studies supported progression of BLU-945 into clinical studies, and it is currently in phase 1/2 clinical trials for treatment-resistant EGFR-driven NSCLC.
Organizational Affiliation:
Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States.
